07:27 AM EST, 02/24/2025 (MT Newswires) -- BioCryst Pharmaceuticals ( BCRX ) reported Q4 adjusted loss Monday of $0.13 per diluted share, narrower from a loss of $0.28 a year earlier.

Four analysts polled by FactSet expected loss of $0.06.

Revenue for the quarter ended Dec. 31 was $131.5 million, up from $93.4 million a year earlier. Analysts surveyed by FactSet expected $130.1 million.

BioCryst Pharmaceuticals ( BCRX ) now expects full year 2025 total revenue of $560 million and $575 million, compared with the previous forecast of $540 million to $560 million. Analysts surveyed by FactSet expect $548.9 million.

Shares were down 3% in premarket activity.